Lowell Therapeutics
Michelle Merrigan, Ph.D. has more than 11 years of experience in clinical development. She specializes in early clinical development and has managed strategy, research, content creation, and agency communications for multiple submissions. Michelle has developed clinical trial protocols from planning through report writing, publication, and regulatory filings. Regulatory submissions include 4 NDAs, 3 MAAs, 5 INDs, 4 Pre-INDs, and 1 IDE. Michelle’s expertise spans multiple therapeutic areas, including critical care medicine, infectious diseases, gastroenterology, and oncology. Prior to entering the pharmaceutical industry, Michelle conducted basic and translational research in the academic environment for more than 10 years. Michelle earned her Ph.D. in Microbiology and Immunology from Loyola University Chicago.
This person is not in any offices
Lowell Therapeutics
Lowell Therapeutics is developing a breakthrough product and a company that makes a real difference in the lives of critically ill patients in the ICU. The phase 3 primary endpoint for their product, Niyad, will be met by proving it anti-coagulates blood.